Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda (NYSE:TAK) ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant. When Takeda CEO ...

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 ...

Homelander (The Boys), and Takeda Takahashi. T-1000, however, is coming as part of Kombat Pack 2, alongside Scream's Ghostface, Conan the Barbarian, Noob Saibot (voiced by Kaiji Tang) Cyrax ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...

Takeda continues to advance multiple late-stage programs and is on track for three Phase 3 data readouts within the calendar year 2025. The company expects three regulatory filings in FY2025 ...

The Mortal Kombat 1 Kombat Pack grants access to 11 DLC characters, but the release dates for these MK1 kombatants are all a ...

TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...

Kombat Pack 1 currently includes Omni-Man, Quan Chi, Peacemaker, Ermac, Homelander, and Takeda Takahashi. T-1000 will be part of Kombat Pack 2 alongside Ghost Face, Conan the Barbarian ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...